CLAIMS

[Claim 1]

A method for producing a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, the method comprising:

culturing, in the presence of an anti-CD30 antibody-drug conjugate (ADC) consisting of Brentuximab vedotin (trade name: Adcetris (registered trademark)) in which a drug having cell-killing activity is bound by a linker cleavable in the intracellular environment, a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells, thereby reducing the content ratio of undifferentiated pluripotent stem cells;

wherein the content ratio of undifferentiated pluripotent stem cells in the cell population is 0.2% or less.

[Claim 2]

Use of a composition comprising an anti-CD30 antibody-drug conjugate (ADC) consisting of Brentuximab vedotin (trade name: Adcetris (registered trademark)) in which a drug having cell-killing activity is bound by a linker cleavable in the intracellular environment in reducing the content ratio of undifferentiated pluripotent stem cells in a method for producing a cell population comprising differentiated cells obtainable by inducing differentiation of pluripotent stem cells,

wherein the content ratio of undifferentiated pluripotent stem cells in the cell population is 0.2% or less.